ENDOCRINE MECHANISMS AND HORMONE ACTION IN CANCER PROGRAM The Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program is a new cancer center program, initiated in 2006. The overall goal of the program is to discover molecular alterations and signatures of hormone-related cancer and translate these findings into new strategies for effective detection, diagnosis, and cure. The program maintains a focus on translational. research on tumors arising from hormone-responsive tissues, including breast and prostate. Three program areas of focus include: 1) detection and diagnosis, 2) prognosis and progression, and 3) targets and therapy. The main specific Scientific Goals of the program are to: Develop innovative strategies and technologies for early detection of primary cancer and monitoring of therapy response and disease recurrence. Improve diagnostic tumor classification, prognostic and predictive marker analyses, and design of pre-clinical models for drug response prediction to facilitate improved tailored treatment. Exploit mechanisms of hormone action for molecular target identification, improved therapy, and prevention of hormone responsive cancer. Several collaborative initiatives are ongoing between the 15 members from 6 departments, supported by peer-reviewed funding of $4.2 million ($2.7 NCI) per year. An P01 program project grant proposal on breast cancer has been submitted from the program. Although this is a new program, several program members have worked collaboratively over many years, with more than 100 joint publications. Since the program's inception in 2006, there have been more than 20 intra-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-12
Application #
8302933
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
12
Fiscal Year
2011
Total Cost
$31,130
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:
Parent, Kristin N; Schrad, Jason R; Cingolani, Gino (2018) Breaking Symmetry in Viral Icosahedral Capsids as Seen through the Lenses of X-ray Crystallography and Cryo-Electron Microscopy. Viruses 10:
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595

Showing the most recent 10 out of 807 publications